Policy Responses to Pharmaceutical Supply Chain Dependence on China
Bipartisan legislation would require Treasury clearance for deals with Chinese firms, while a new law restricts federal biotech procurement.1,2
Industry data cited in reports shows China's large share of drug ingredients and clinical trials, driving regulatory and security concerns.1,2
- Bipartisan legislation introduced in June would subject U.S. pharmaceutical deals with Chinese firms to Treasury Department clearance.1
- A Johns Hopkins study found China supplies more than 60% of essential components needed for U.S. antibiotic manufacturing.2
- The Biosecure Act, signed into law in December 2025, restricts federal procurement of biotechnology from designated companies tied to foreign adversaries.2
- FDA nominee Heidi Overton stated that 'slow and prohibitive' FDA requirements are driving investment to Chinese companies, according to her confirmation hearing testimony.1
- The specific executive order for President Trump's action on synthetic opioid supply chain tariffs, and the current status of pending legislation like Operation TrialBlazer, are not detailed in the available reports.1,2
In June, Representatives John Moolenaar (R-Mich.) and Debbie Dingell (D-Mich.) co-sponsored legislation that would require all U.S. pharmaceutical deals with Chinese companies to be cleared by the Treasury Department.1
This move follows the signing of the Biosecure Act in December 2025, which restricts federal procurement involving biotechnology products from companies tied to foreign adversaries.2
These policy developments respond to industry reports that China produces 45% of global active pharmaceutical ingredients, compared to roughly 3% for the U.S., and accounts for as much as 46% of new drugs tested worldwide.1,2
The Scale of Dependence
Industry reports cited in policy discussions highlight China's dominant role in pharmaceutical manufacturing and research. Fox News reported that China produces 45% of global active pharmaceutical ingredients, while the U.S. produces roughly 3%.2
A Johns Hopkins study found China supplies more than 60% of essential components U.S. manufacturers need for antibiotics, according to a Fox News report.2
KFF Health News reported that China accounted for as much as 46% of new drugs tested around the world in 2025, and that U.S. pharmaceutical companies are signing billion-dollar contracts with Chinese firms.1
Legislative and Executive Responses
The legislative response includes a bipartisan bill introduced in June by Representatives John Moolenaar and Debbie Dingell. The proposed legislation would require all U.S. pharmaceutical deals with Chinese companies to be cleared by the Treasury Department.1
Separately, the Biosecure Act was signed into law in December 2025, restricting federal procurement involving biotechnology products from designated companies tied to foreign adversaries, Fox News reported.2
On the executive side, President Trump took executive action on tariffs targeting the synthetic opioid supply chain, according to Fox News.2
Regulatory Dynamics and Industry Shifts
FDA nominee Heidi Overton, in her Sept. 24 confirmation hearing, stated that 'slow and prohibitive' FDA requirements are driving investment to Chinese companies, KFF Health News reported.1
The same report stated that the Trump administration launched Operation TrialBlazer in June to speed FDA regulatory processes.1
The FDA, through HHS spokesperson Emily Hilliard, cautions patients about potential safety and quality risks of obtaining treatments outside the U.S. regulatory system, KFF Health News reported.1
The Trump administration launches Operation TrialBlazer to speed FDA regulatory processes, KFF Health News reported.1
Representatives John Moolenaar (R-Mich.) and Debbie Dingell (D-Mich.) co-sponsor legislation requiring Treasury clearance for U.S. pharmaceutical deals with Chinese companies, KFF Health News reported.1
FDA nominee Heidi Overton testifies at her confirmation hearing that 'slow and prohibitive' FDA requirements are driving investment to Chinese companies, KFF Health News reported.1
The Biosecure Act is signed into law, restricting federal procurement involving biotechnology products from designated companies tied to foreign adversaries, Fox News reported.2
- The exact citation (authors, publication, date) for the Johns Hopkins study on antibiotic components.
- The Public Law number and effective date for the reportedly enacted Biosecure Act.
- The specific executive order number and details for Trump's action on synthetic opioid supply chain tariffs.
- The percentage of U.S. (not global) active pharmaceutical ingredients sourced from China.
- Which specific drug categories are most vulnerable to supply disruption.
- The current status and details of pending legislation (beyond the Moolenaar-Dingell bill) and executive actions like Operation TrialBlazer.
- 1.
- 2.